KCNH2 and type 2 diabetes mellitus: Currently, DHBER is a drug candidate for the treatment of type 2 diabetes [29–30], can reduce the atherosclerotic plaque size [31], has therapeutic potential for myotonic dystrophy type I due to its central nervous system effects [32], inhibits both hERG current and the expression of hERG protein [33], inhibits the pancreatic lipase [34], shows antiradical, revitalizing and antifibrotic properties for dermatological applications [35], manifests a synergic effect with antibiotics [36], and displays antitumoral activities [37–38].